JP2001523959A5 - - Google Patents

Download PDF

Info

Publication number
JP2001523959A5
JP2001523959A5 JP1998546254A JP54625498A JP2001523959A5 JP 2001523959 A5 JP2001523959 A5 JP 2001523959A5 JP 1998546254 A JP1998546254 A JP 1998546254A JP 54625498 A JP54625498 A JP 54625498A JP 2001523959 A5 JP2001523959 A5 JP 2001523959A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998546254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/007968 external-priority patent/WO1998048009A2/en
Publication of JP2001523959A publication Critical patent/JP2001523959A/ja
Publication of JP2001523959A5 publication Critical patent/JP2001523959A5/ja
Ceased legal-status Critical Current

Links

JP54625498A 1997-04-21 1998-04-21 疾患のリボザイム処置のための物質および方法 Ceased JP2001523959A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4449297P 1997-04-21 1997-04-21
US60/044,492 1997-04-21
US4614797P 1997-05-09 1997-05-09
US60/046,147 1997-05-09
PCT/US1998/007968 WO1998048009A2 (en) 1997-04-21 1998-04-21 Materials and methods for ribozyme treatment of retinal diseases

Publications (2)

Publication Number Publication Date
JP2001523959A JP2001523959A (ja) 2001-11-27
JP2001523959A5 true JP2001523959A5 (enExample) 2005-12-02

Family

ID=26721633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54625498A Ceased JP2001523959A (ja) 1997-04-21 1998-04-21 疾患のリボザイム処置のための物質および方法

Country Status (8)

Country Link
US (1) US6225291B1 (enExample)
EP (1) EP0977841A2 (enExample)
JP (1) JP2001523959A (enExample)
AU (1) AU735788B2 (enExample)
BR (1) BR9808606A (enExample)
CA (1) CA2287508A1 (enExample)
NZ (1) NZ500427A (enExample)
WO (1) WO1998048009A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500427A (en) 1997-04-21 2002-12-20 Univ Florida The use of ribozyme treatment for retinal diseases
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6485976B1 (en) 1999-04-30 2002-11-26 City Of Hope Use of adeno-associated virus (AAV) to deliver genes
JP2002542805A (ja) * 1999-04-30 2002-12-17 ユニバーシティ オブ フロリダ アデノ随伴ウイルス送達リボザイム組成物および使用方法
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20030003582A1 (en) * 2001-05-08 2003-01-02 Tranzyme, Inc. Trans-viral vector mediated gene transfer to the retina
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
ES2334125T3 (es) * 2002-11-04 2010-03-05 University Of Massachusetts Interferencia de arn especifico de alelos.
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
EP1937066A4 (en) 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
EP2140004B1 (en) * 2007-04-12 2022-01-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Genetic suppression and replacement
MX2011005851A (es) 2008-12-04 2011-07-29 Opko Opthalmics Llc Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
US8450473B2 (en) 2009-04-30 2013-05-28 The Research Foundation Of State University Of New York Compositions and methods for therapy of macular degeneration
EA202091105A1 (ru) 2010-04-23 2020-12-30 Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Композиции гуанилатциклазы и способы лечения врожденного амавроза лебера типа 1 (lca1)
EP4600255A3 (en) 2014-05-02 2025-10-22 Genzyme Corporation Aav vectors for retinal and cns gene therapy
EP4012035B1 (en) 2014-09-16 2024-11-06 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
CA2961523A1 (en) 2014-09-16 2016-03-24 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
BR112017017178A2 (pt) 2015-02-26 2018-04-03 Ionis Pharmaceuticals Inc moduladores específicos de alelo de rodopsina de p23h
US11653636B2 (en) * 2019-11-15 2023-05-23 University Of Ulsan Foundation For Industry Cooperation Method of making a rat model of retinal degeneration and rat model made thereby
AU2021213786A1 (en) 2020-01-29 2022-09-22 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5646020A (en) 1992-05-14 1997-07-08 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes for preferred targets
US5498539A (en) 1992-07-02 1996-03-12 Daiichi Pharmaceutical Co., Ltd. Bovine endothelial nitric oxide synthase nucleic acids
US5639655A (en) 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5646031A (en) 1995-05-16 1997-07-08 Northern Illinois University SArMV and sCYMVI hairpin ribozymes
GB9519299D0 (en) * 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
GB9604449D0 (en) 1996-03-01 1996-05-01 Farrar Gwyneth J Genetic strategy ii
NZ500427A (en) 1997-04-21 2002-12-20 Univ Florida The use of ribozyme treatment for retinal diseases
EP0977880A2 (en) 1997-04-21 2000-02-09 University Of Florida Materials and methods for treatment of retinal diseases

Similar Documents

Publication Publication Date Title
JP2000509912A5 (enExample)
JP2000509942A5 (enExample)
JP2000510751A5 (enExample)
JP2000507042A5 (enExample)
JP2001524836A5 (enExample)
JP2001523240A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2002508747A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2001508794A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2001514522A5 (enExample)
JP2000508680A5 (enExample)
JP2000509853A5 (enExample)
JP2000510247A5 (enExample)
JP2000510969A5 (enExample)
JP2001524146A5 (enExample)
JP2000508102A5 (enExample)
JP2000508836A5 (enExample)
JP2001523959A5 (enExample)
JP2000509818A5 (enExample)
JP2000507434A5 (enExample)